Introduction to a Revolutionary Cancer Approach This treatment starts with T cells from the patient. Doctors add receptors to spot…
Browsing: Melanoma Skin Cancer Treatment
Melanoma and Skin Cancer Treatment Resources
Melanoma and skin cancer treatment is advancing rapidly, and OncologyTube’s Melanoma and Skin Cancer Treatment category is your trusted source for the latest insights. Discover expert-led videos, clinical trial updates, and research from leading oncologists. Whether you’re exploring immunotherapy, targeted therapies like BRAF inhibitors, or surgical options, our curated content supports patients and professionals. Learn about breakthroughs like the KEYNOTE-054 trial for adjuvant immunotherapy in melanoma.
Why Trust OncologyTube?
We feature renowned experts like Dr. Jeffrey Weber, a melanoma specialist, delivering credible and actionable insights. Our partnerships with top institutions ensure reliable, up-to-date information.
Latest Melanoma and Skin Cancer Research
Stay informed with cutting-edge studies, such as ASCO 2025 updates on PD-1 inhibitors and combination therapies. Our videos simplify complex topics like sentinel lymph node biopsy and UV prevention for patients and caregivers.
Patient and Professional Resources
OncologyTube provides tools for both patients and providers. Patients can access support resources, while professionals find updates on guidelines from ASCO and NCCN. Watch interviews addressing treatment challenges, such as managing metastatic melanoma.
Explore More
Dive into related content like Dr. Weber’s video on melanoma immunotherapy or visit our Immunotherapy Category. For guidelines, explore the National Cancer Institute or ASCO.
TIL Therapy Breakthroughs for Oncologists and Oncology Professionals Tumor-Infiltrating Lymphocyte (TIL) therapy is transforming melanoma care and continues to provide…
Introduction to Neoadjuvant Therapy for Melanoma Neoadjuvant therapy is changing how we treat melanoma, offering big benefits over traditional adjuvant…
Oncology changes quickly. The melanoma treatment updates 2025 from the ASCO Annual Meeting offer vital help. Dr. Gino K. In,…
The 2025 Cell article by Catherine M. Phelps et al. from the University of Pittsburgh reveals a key connection between…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
Dr. Omid Hamid from The Angeles Clinic goes over his favorite presentations coming up at ASCO 2024. Should these be…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T.…
What is the new treatment for metastatic melanoma? On February 16, 2024, the medical community witnessed a significant milestone in…
By. Katy Tsai, MDDate: 11/21/2023Katy Tsai, MD, discusses the progress in cancer survivorship on a national scale, citing data from…
By: Allison Betof Warner, MD, PhD, StanfordDate: 11/13/2023 From: MOASCImmuno-Oncology Determining Optimal Treatment Duration Transcript: The question of how long…
By. Mohammed Dar, MDDate. November 02, 2023Mohammed Dar, MD, observed significant advancements in the treatment of metastatic uveal melanoma, particularly…
By. Neil Gross, MDDate. October 26, 2023 In a discussion detailing the primary outcomes of the Phase 2 trial for…
KEYNOTE-716 trial brings to light the impressive efficacy of pembrolizumab as an adjuvant therapy for stage IIB or IIC melanoma.…
Omid Hamid, MD – The Angeles Clinic This phase 1/2 study evaluated the combination therapy of retifanlimab, INCAGN02385 (Anti–LAG-3), and…
Jason Luke, MD, FACP, a renowned medical professional affiliated with the University of Pittsburgh Medical Center (UPMC), recently conducted a…
Omid Hamid, MD from The Angeles Clinic & Research Institute reports on the best Cutaneous Treatments from ASCO 2023 and…
IDE196 Solid Tumors GNAQ/11 Mutations or PRKC Fusions [2022] What is IDE196? And How Will It Help Patients With Solid…
SWOG S1801 Trial: Pembro After or Before Surgery? [2022] It is not yet known which type of immunotherapy, adjuvant or…
M14TIL Trial: TIL Compared to Std. Ipilimumab [2022] This is the first experiment to use tumor-infiltrating lymphocytes (TIL) in metastatic…
Shahid Gilani, MD from the University Hospital Of North Midlands speaks about Hypofractionated radiotherapy as a definitive treatment for Basal…
Question and Answer Session Justin Moyers, MD – ASCO 2022 Melanoma Overview: MOASC Spotlight https://oncologytube.com/v/41283 Justin Moyers, MD Exit Interview…
ASCO 2022 Melanoma (American Society of Clinical Oncology) In-Depth Slides: MOASC Spotlight on Oncology I’ll do a brief reminder of…
ASCO 2022 Melanoma Overview: MOASC Spotlight  KEYNOTE-716 Study  Today, we talked about some of the exciting new discoveries…
Audio: The FDA approval of multiple drugs um for the treatment of metastatic unresectable melanoma led to uh the concept…
T-Vec: + Pembro Advanced Melanoma MASTERKEY-115 Trial Dr Gastman By Brian Gastman, MD The FDA’s approval of multiple drugs for…
Transcript: The FDA approval of multiple drugs for the treatment of metastatic unresectable melanoma led to the concept that we…
Transcript – KEYNOTE-716 New Facts You Need To Know – Article Question – Please Tell Us About The KEYNOTE-716 Study.…
Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and…
Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and…
Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this audio, he…
Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this video, he…
Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In…
Mansi Saxena, Ph.D., Associate Facility Director, Vaccine and Cell Therapy Laboratory at Icahn School of Medicine at Mount Sinai. In…
Orphan Drug Designation Update: IDEAYA Biosciences inc Darovasertib and Crizotinib Synthetic Lethal Combination Expansion Dose in Heavily Pre-Treated Metastatic Uveal…
Meredith McKean, MD, Sarah Cannon Research Institute at Tennessee Oncology, Associate Director, Melanoma and Skin Cancer Research speaks about IDEAYA…
Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab)…
Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab)…
Philip O. Scumpia, MD, Ph.D. and Professor Aydogan Ozcan, Ph.D. from UCLA Health and UCLA Samueli Electrical & Computer Engineering…
Philip O. Scumpia, MD, Ph.D. and Professor Aydogan Ozcan, Ph.D. from UCLA Health and UCLA Samueli Electrical & Computer Engineering…
Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania…
Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania…
Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021…
Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021…
Prof. Dr. med. Dirk Schadendorf, Universitätsklinikum Essen speaks about the ESMO 2021 Abstract – 1091TiP – STARBOARD: Randomized phase III…
Prof. Dr. med. Dirk Schadendorf, Universitätsklinikum Essen speaks about the ESMO 2021 Abstract – 1091TiP – STARBOARD: Randomized phase III…
Joleen M. Hubbard, MD, Oncology Department, Mayo Clinic speaks about the ESMO 2021 Abstract – 507TiP – PRESERVE 1: A…
Jason J. Luke, MD, FACP, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center speaks about ESMO 2021 Abstract #LBA3, Presidential Symposium:…
Jason J. Luke, MD, FACP, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center speaks about ESMO 2021 Abstract #LBA3, Presidential Symposium:…
LluÃs Espinosa, MD from IMIM-Hospital del Mar and CIBERONC speaks about Optimising Metastatic Melanoma Therapy By Combining Two Treatments.Link to…
Sajeve Thomas, MD, an oncologist and hematologist at the Orlando Health Cancer Institute speaks about Using A Patient’s Own Tumor…
Sajeve Thomas, MD, an oncologist and hematologist at the Orlando Health Cancer Institute speaks about Using A Patient’s Own Tumor…
LluÃs Espinosa, MD from IMIM-Hospital del Mar and CIBERONC speaks about Optimising Metastatic Melanoma Therapy By Combining Two Treatments.Link to…
Jonathan Zager, MD from H. Lee Moffitt Cancer Center & Research Institute speaks about ASCO 2021 Abstract – Percutaneous hepatic…
Jonathan Strosberg, MD from H. Lee Moffitt Cancer Center & Research Institute speaks about the ASCO 2021 Abstract – Final…
Ana Maria Arance, MD from the Hospital Clinic Barcelona speaks about ASCO 2021 Abstract – Lenvatinib (len) plus pembrolizumab (pembro)…
Pauline Funchain, MD, Medical Oncologist/Cancer Genomics at Cleveland Clinic speaks about the ASCO 2021 Abstract – Final analysis of overall…
Adam C. Berger, MD, FACS, Chief, Melanoma and Soft Tissue Surgical Oncology, Associate Director for Shared Resources at Rutgers Cancer…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with…
Iván Márquez Rodas MD, Ph.D. of the Medical Oncology Department, Hospital Gregorio Marañon, Madrid, Spain Speaks about Highlight & Pivotal…
Douglas Johnson, MD, MSCI, associate professor of Medicine at Vanderbilt University Medical Center and clinical director of Melanoma at Vanderbilt-Ingram…
Adil Daud, MD Professor of Medicine at The University of California, San Francisco, Director of the Melanoma Clinical Research, and…
Professor Arthur D. Lander, M.D., Ph.D. of UCI University of California, Irvine speaks about Dynamics of nevus development implicate cell…
Alexander Stratigos, M.D., Professor of Dermatology/Or Investigator of the University of Athens Medical School at Andreas Sygros Hospital explains the…
Ana Maria Arance Fernandez, MD of Hospital ClÃnic de Barcelona, Barcelona, Spain speaks on her ESMO abstract – LBA44 -…
Alexander Eggermont, MD of Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay explains the ESMO 2020 abstract LBA46 -…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director, Experimental Therapeutics Cedars Sinai Foundation discusses the Multi-Modality Management of Melanoma in the…
Craig Slingluff, MD of @UVACancerCenter answers the study design and what is next for phase III data for a melanoma…
Craig Slingluff, MD of @UVACancerCenter discusses the phase III data for a melanoma vaccine, seviprotimut-L. ____________ — MAVIS Study Identifies…
— MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients –…
Viruses designed to kill cancer cells are already used to treat one skin cancer and are commonly studied in other…
John Fruehauf, MD disucsses whether the CheckMate 204 data will affect treatment selection in brain metastases
John Fruehauf, MD of UC Irvine Health discusses new first-line therapy for asymptomatic melanoma brain metastases. Â Â Â Â …
John Fruehauf, MD of UC Irvine Health explains clinicians could change the way they manage their patients by lowering doses…
John Fruehauf, MD provides insight on how to address toxicity that is causing colitis.
John Fruehauf, MD of UC Irvine Health discusses lowering toxicity through alternate dosing.
John Fruehauf, MD of UC Irvine Health presents whether data practice will change for clinicians.
John Fruehauf, MD of UC Irvine Health explains how INMC data has impacted surgical oncologists.
Michael B. Atkins at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology follows up on…
Keith T. Flaherty, M.D. Of Array BioPharma Discusses Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of…
Robert Rifkin MD Of US Oncology Research Discusses Measuring BCMA: Do Not Have To Wait For Relapse, We Know When…
Robert Rifkin MD Of US Oncology Research Discusses Trial Updates At ASCO: Approval Of Daratumumab In Combination With Revlimid Or…
Robert Rifkin MD Of US Oncology Research Discusses Isatuximab & Daratumumab: When You Add Isatuximab To Pomalidomide & Dexamethasone Outcomes…
Robert Rifkin MD Of US Oncology Research Discusses Connect MM Myeloma Disease Registry: This Is A Special Group Of Myeloma…
Dr. Michael Atkins MD Of Georgetown University Discusses Who Should Get Ipi:Nivo VS NIVO Monotherapy: Patients With Elevated LDH, BRAF…
Dr. Michael Atkins MD Of Georgetown University Discusses CHECKMATE-004 Trial Results: 57% Of Patients Were Alive At 4 Years, Treatment…
Alexander Guminski MD Of The University of Sydney Discusses Where Is Cemiplimab Best Placed: Deploying Early As A Stand Alone…
Alexander Guminski MD Of The University of Sydney Discusses Phase 2 Study Of Cemiplimab: Response Rate Of 49 Estimated PFS…
Elizabeth Buchbinder MD Of DFCI Discusses Mucosal Melanoma: Rare Form Of Melanoma With Much Lower Mutational Burden.
Omid Hamid MD @OmidHamidMD Of The Angeles Clinic Discusses First Line Melanoma Trial: Utilizes Microbiome Manipulation In Newly Diagnosed Patients…
Jessica Geiger MD Of The Cleveland Clinic Discusses Are There Therapies For Squamous Cell Carcinoma: PD-1 Inhibitor Approved For Metastatic…
Jessica Geiger MD Of The Cleveland Clinic Discusses KEYNOTE-630: Randomizing Patients To Get Either Pembrolizumab Or Placebo.
Jessica Geiger MD Of The Cleveland Clinic Discusses Recruiting Patients For KEYNOTE-630: Looking For Patients With High Risk Features Like…
Ahmad Tarhini Md, PhD of the Winship Cancer Center discusses the United States Intergroup E1609 A phase III randomized study…
Marcus Butler, MD discusses TBI-1301-Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical…
Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Grant McArthur, MBBS, BMedSc, PhD,…
Great strides have been made in the treatment of advanced melanoma; these developments are now being translated into the adjuvant…
Melanoma that has metastasized to the brain is extremely high risk, and such metastasis is more likely in patients with…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Paolo Ascierto, MD, of the…
While treatments for melanoma have been steadily improving over recent years, patients with brain metastases have consistently had poor outcomes.…
A variety of new therapeutics for melanoma are on the horizon, including IDO, immune checkpoint, LAG-3 and HDAC inhibitors. Here,…
The treatment of melanoma is undergoing exciting advancements, as discussed here by Paolo Ascierto, MD, of the National Cancer Institute…
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, hosted an array of exciting clinical trials…
Paul Nghiem, MD, PhD, University of Washington, shares MCC Needs to be Managed in Multidisciplinary Way | Oncology, Surgery, Radiation…
Paul Nghiem, MD, PhD, University of Washington, shares Patients Who Dont Respond to Checkpoint Therapy | Collaborating to Pick Apart…
Paul Nghiem, MD, PhD, University of Washington, shares Collaborative Community Working to Understand MCC | Do Not Need Mutational Burden…
Paul Nghiem, MD, PhD, University of Washington, shares Cannot Predict Who Responds to Immunotherapies | Response is 60% or More…
Paul Nghiem, MD, PhD, University of Washington, shares Immunotherapy better than Chemo-Therapy More Durable, Works Better in the Frontline at…
Paul Nghiem, MD, PhD, University of Washington, shares Immunotherapy & Chemo-Therapy with MCC Response is 60% or More If therapy…
Eric A. Klein, MD, Cleveland Clinic, explains The Circulating Cell-free Genome Atlas Study | Hope to Develop Multi-Cancer Screening Test…
Paul Nghiem, MD, PhD, University of Washington, explains Avelumab, for Metastatic Merkel Cell Carcinoma | Observed Responses are Durable at…
From the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference held in Denver, CO, Jacob Kettle, PharmD, BCOP, of the University…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about Adjuvant Data Changing Clinical Practice Moving into Anti-PD-1 monotherapy, and…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economics Outcome Research More Important Guiding clinicians & policy makers, survival…
Martina A. Sersch, MD, Executive Medical Director at Amgen Inc., shares Safety Profile of Once-Weekly Regimen Was comparable opposed to…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, talks about ECOG-ACRIN EA6134 Ipilimumab + Nivolumab vs. Dabrafenib + Trametinib at…
Ahmad Tarhini, MD, PhD, Cleveland Clinic Main Campus, shares Economic Outcome Analysis for BRAF Melanoma Anti-CD4+PD-1, & Anti-PD-1 both followed…